| Amy M Donley, SLP | |
|
515 Jewell St, Alma, NE 68920-2067 | |
| (308) 928-2131 | |
| (308) 928-2763 |
| Full Name | Amy M Donley |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 515 Jewell St, Alma, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104883545 | NPI | - | NPPES |
| 47065477700 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1147 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amy M Donley, SLP Po Box 858, Holdrege, NE 68949-0858 Ph: (308) 995-6585 | Amy M Donley, SLP 515 Jewell St, Alma, NE 68920-2067 Ph: (308) 928-2131 |
News Archive
Dr. Jason Gilliland, a Scientist at Children's Health Research Institute, Lawson Health Research Institute and Director of the Human Environments Analysis Laboratory at Western University, is combining health research with geography to understand the connection between children's nutrition and their local neighbourhoods.
Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease.
QIAGEN N.V. today announced the commercial launch in India of its careHPV™ Test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with limited healthcare infrastructure, such as areas lacking electricity, water or laboratories.
The widespread practice of incentivizing mammogram completion via cash payments, typically by insurance companies and ranging from $10 to $250, is unethical according to a Viewpoint article published this week in JAMA by an expert from the Perelman School of Medicine at the University of Pennsylvania.
Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.
› Verified 1 days ago
Jenni L Guthrie, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 515 Jewell St, Alma, NE 68920 Phone: 308-928-2131 |